Show simple item record

dc.contributor.authorRustin, GJ
dc.contributor.authorMead, GM
dc.contributor.authorStenning, SP
dc.contributor.authorVasey, PA
dc.contributor.authorAass, N
dc.contributor.authorHuddart, RA
dc.contributor.authorSokal, MP
dc.contributor.authorJoffe, JK
dc.contributor.authorHarland, SJ
dc.contributor.authorKirk, SJ
dc.contributor.authorNational Cancer Research Institute Testis Cancer Clinical Studies Group
dc.date.accessioned2018-07-26T11:03:15Z
dc.date.issued2007-04
dc.identifier.citationJournal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, 25 (11), pp. 1310 - 1315
dc.identifier.issn0732-183X
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2165
dc.identifier.eissn1527-7755
dc.identifier.doi10.1200/jco.2006.08.4889
dc.description.abstractPurpose Surveillance is a standard management approach for stage I nonseminomatous germ cell tumors (NSGCT). A randomized trial of two versus five computed tomography (CT) scans was performed to determine whether the number of scans influenced the proportion of patients relapsing with intermediate- or poor-prognosis disease at relapse.Methods Patients with clinical stage I NSGCT opting for surveillance were randomly assigned to chest and abdominal CT scans at either 3 and 12 or 3, 6, 9, 12, and 24 months, with all other investigations identical in the two arms. Three of five patients were allocated to the two-scan schedule. Four hundred patients were required.Results Two hundred forty-seven patients were allocated to a two-scan and 167 to five-scan policy. With a median follow-up of 40 months, 37 relapses (15%) have occurred in the two-scan arm and 33 (20%) in the five-scan arm. No patients had poor prognosis at relapse, but two (0.8%) of those relapsing in the two-scan arm had intermediate prognosis compared with 1 (0.6%) in the five-scan arm, a difference of 0.2% (90% CI, -1.2% to 1.6%). No deaths have been reported.Conclusion This study can rule out with 95% probability an increase in the proportion of patients relapsing with intermediate- or poor-prognosis disease of more than 1.6% if they have two rather than five CT scans as part of their surveillance protocol. CT scans at 3 and 12 months after orchidectomy should be considered a reasonable option in low-risk patients.
dc.formatPrint
dc.format.extent1310 - 1315
dc.languageeng
dc.language.isoeng
dc.subjectNational Cancer Research Institute Testis Cancer Clinical Studies Group
dc.subjectHumans
dc.subjectNeoplasms, Germ Cell and Embryonal
dc.subjectTesticular Neoplasms
dc.subjectNeoplasm Recurrence, Local
dc.subjectDisease Progression
dc.subjectTomography, X-Ray Computed
dc.subjectNeoplasm Staging
dc.subjectPrognosis
dc.subjectChi-Square Distribution
dc.subjectAdult
dc.subjectAustralia
dc.subjectNorway
dc.subjectNew Zealand
dc.subjectMale
dc.subjectRandomized Controlled Trials as Topic
dc.subjectUnited Kingdom
dc.titleRandomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197--the National Cancer Research Institute Testis Cancer Clinical Studies Group.
dc.typeJournal Article
rioxxterms.versionofrecord10.1200/jco.2006.08.4889
rioxxterms.licenseref.startdate2007-04
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfJournal of clinical oncology : official journal of the American Society of Clinical Oncology
pubs.issue11
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Clinical Academic Radiotherapy (Huddart)
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Clinical Academic Radiotherapy (Huddart)
pubs.publication-statusPublished
pubs.volume25
pubs.embargo.termsNot known
icr.researchteamClinical Academic Radiotherapy (Huddart)en_US
dc.contributor.icrauthorHuddart, Roberten
dc.contributor.icrauthorRustin, Gordonen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record